PMID- 17601558
OWN - NLM
STAT- MEDLINE
DCOM- 20071130
LR  - 20181113
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 570
IP  - 1-3
DP  - 2007 Sep 10
TI  - Central kappa-opioid receptor-mediated antidepressant-like effects of 
      nor-Binaltorphimine: behavioral and BDNF mRNA expression studies.
PG  - 89-96
AB  - kappa-opioid receptor antagonists such as nor-Binaltorphimine (nor-BNI) have been 
      shown to produce antidepressant-like behavioral effects in animal models of 
      depression. The aim of this study was to investigate further the duration of 
      centrally administered nor-BNI-induced antidepressant-like actions measured by 
      both behavior and brain-derived neurotrophic factor (BDNF) gene expression. In 
      addition, antagonist studies were conducted to determine the role of opioid 
      receptor subtypes and the time course of nor-BNI's pharmacological actions. 
      Antidepressant-like behavioral effects were measured by decreased immobility in 
      the rat forced swim test and BDNF mRNA expression was determined by in situ 
      hybridization. Centrally administered nor-BNI (20 microg, i.c.v.) decreased 
      immobility and increased BDNF mRNA expression in the hippocampus on day 1, not on 
      days 3-14, post-administration. Systemic administration of selective mu-, delta- 
      and kappa-opioid receptor antagonists did not block nor-BNI-induced 
      antidepressant-like effects. In contrast, i.c.v. administration of nor-BNI 7 or 
      14 days earlier significantly blocked subsequent nor-BNI-induced decreased 
      immobility and upregulation of BDNF mRNA expression. Although the duration of 
      nor-BNI's antidepressant-like effects did not synchronize with that of its 
      kappa-opioid receptor antagonist effects, this study is the first to show that 
      centrally administered nor-BNI, like most clinically used antidepressants, can 
      upregulate BDNF mRNA expression in the rat hippocampus. These findings further 
      demonstrate that central kappa-opioid receptor mediates antidepressant-like 
      effects of nor-BNI measured by both behavior and BDNF gene expression.
FAU - Zhang, Huina
AU  - Zhang H
AD  - Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 
      48109, USA.
FAU - Shi, Yong-Gong
AU  - Shi YG
FAU - Woods, James H
AU  - Woods JH
FAU - Watson, Stanley J
AU  - Watson SJ
FAU - Ko, Mei-Chuan
AU  - Ko MC
LA  - eng
GR  - P01 DA000254-320004/DA/NIDA NIH HHS/United States
GR  - R01 DA013685-03/DA/NIDA NIH HHS/United States
GR  - T32 DA007268-10/DA/NIDA NIH HHS/United States
GR  - MH42251/MH/NIMH NIH HHS/United States
GR  - T32 DA007281/DA/NIDA NIH HHS/United States
GR  - P01 MH042251/MH/NIMH NIH HHS/United States
GR  - DA13685/DA/NIDA NIH HHS/United States
GR  - P01 DA000254/DA/NIDA NIH HHS/United States
GR  - P01 MH042251-20/MH/NIMH NIH HHS/United States
GR  - T32 DA007268/DA/NIDA NIH HHS/United States
GR  - R01 DA013685/DA/NIDA NIH HHS/United States
GR  - DA00254/DA/NIDA NIH HHS/United States
GR  - DA07281/DA/NIDA NIH HHS/United States
GR  - K21 DA000254/DA/NIDA NIH HHS/United States
GR  - P50 DA000254/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20070609
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Antidepressive Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Opioid, kappa)
RN  - 105618-27-7 (binaltorphimine)
RN  - 5S6W795CQM (Naltrexone)
SB  - IM
MH  - Animals
MH  - Antidepressive Agents/*pharmacology
MH  - Behavior, Animal/*drug effects
MH  - Brain/drug effects/metabolism
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Gene Expression Regulation/drug effects
MH  - Male
MH  - Naltrexone/*analogs & derivatives/pharmacology
MH  - RNA, Messenger/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Opioid, kappa/*antagonists & inhibitors
MH  - Swimming
PMC - PMC2031926
MID - NIHMS29730
EDAT- 2007/07/03 09:00
MHDA- 2007/12/06 09:00
PMCR- 2008/09/10
CRDT- 2007/07/03 09:00
PHST- 2007/01/03 00:00 [received]
PHST- 2007/05/17 00:00 [revised]
PHST- 2007/05/22 00:00 [accepted]
PHST- 2007/07/03 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/07/03 09:00 [entrez]
PHST- 2008/09/10 00:00 [pmc-release]
AID - S0014-2999(07)00651-6 [pii]
AID - 10.1016/j.ejphar.2007.05.045 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2007 Sep 10;570(1-3):89-96. doi: 10.1016/j.ejphar.2007.05.045. 
      Epub 2007 Jun 9.